Search the Newsreel

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

Adicet Bio (ACET) is set to release clinical data this quarter for its lead autoimmune program, ADI-001 (prula-cel), which targets lupus nephritis (LN) and systemic lupus erythematosus (SLE). The company expects to include data from 22 enrolled patients, with 13 having at least 12 …

Adicet Bio at Canaccord Genuity: lupus data drives next step By Investing.com

Adicet Bio presented at Canaccord Genuity's 46th Annual Growth Conference, highlighting its off-the-shelf cell therapy program (ADI-001 or prula-cel) for lupus nephritis and systemic lupus erythematosus. The company plans to release the largest dataset for an allogeneic off-the-shelf cell therapy in lupus, with 22 …

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Price to sales forward of Adicet Bio, Inc. – NASDAQ:ACET

The article focuses on the "Price to sales forward" financial metric for Adicet Bio, Inc. (NASDAQ: ACET). It presents this data within the context of TradingView's financial analysis tools, indicating that the market for ACET was closed at the time of viewing.

Press Release Service: Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Adicet Bio reported its second quarter 2026 financial results and provided business updates, highlighting the advancement of its allogeneic gamma delta T cell therapies. Key updates include a comprehensive Phase 1 clinical update for prulacabtagene leucel (prula-cel) in lupus nephritis and systemic lupus erythematosus …

Adicet Bio Inc (ACET) Earnings Forecast: Future EPS & Revenue Growth Estimates

Guggenheim cuts Adicet Bio stock price target to $90 on cash position

Guggenheim lowered its price target for Adicet Bio Inc. (NASDAQ:ACET) to $90 from $100, while maintaining a Buy rating, citing the company's updated spend rate and cash position. Adicet holds more cash than debt and has a funding runway into the second half of …

Adicet Bio, Inc. 2Q 2026: Revenue $0 Net loss $(21.4)M, EPS $(1.99) — 10-Q Summary

Adicet Bio, Inc. (ACET) reported no product revenue for the second quarter of 2026, with a net loss of $(21.4)M, a significant improvement from the $(31.2)M loss in the prior-year quarter. The diluted net loss per share was $(1.99), down from $(5.48) year-over-year. The …

Adicet Bio, Inc. Stock 12‑Month Price Target Cut to $34.4, Implies 276% Upside

The average 12-month price target for Adicet Bio, Inc. (ACET) stock has been lowered from $36.4 to $34.4 by five analysts, with individual forecasts ranging from $18 to $90 per share. This updated target suggests a potential upside of approximately 276% from its closing …

Adicet Bio Plans Lupus Therapy Update With 22 Patients in 3Q

Adicet Bio reported a net loss of $21.4 million for Q2 2026 and expects to provide a Phase 1 clinical update for its lupus nephritis (LN) and systemic lupus erythematosus (SLE) therapy, prulacabtagene leucel (prula-cel), in Q3 2026, including data from 22 patients. The …

ADICET Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary

ADICET Bio, Inc. has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters via TradingView News, provides details on the company's financial performance during this period. Readers can access the full report for comprehensive information.

Adicet Bio (NASDAQ:ACET) Posts Earnings Results, Misses Estimates By $0.30 EPS

Adicet Bio (NASDAQ:ACET) reported a quarterly loss of $1.99 per share, missing the consensus estimate by $0.30. The company's stock traded down slightly to $9.11, significantly below its 52-week high, despite institutional investors owning a large percentage and analysts maintaining a "Moderate Buy" rating …

Spacetalk (ASX:SPA) Secures Funding to Support Technology Platform Expansion

Adicet Bio Inc Actuals & Estimates (NASDAQ:ACET)

This article provides an overview of Adicet Bio, Inc. (NASDAQ: ACET) stock, detailing its current price, market capitalization, historical highs and lows, and recent performance. It also includes analyst forecasts, earnings information, revenue data, and discusses volatility, employee count, and investment considerations.

Adicet Bio Inc (ACET) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides an overview of Adicet Bio Inc (ACET), including its stock performance and market capitalization. However, it explicitly states that relevant data regarding the company's revenue breakdown by business segments and regions has not been disclosed by the company yet. …

Adicet Bio (NASDAQ:ACET) Share Price Passes Above 200 Day Moving Average - Time to Sell?

Adicet Bio (NASDAQ:ACET) saw its stock price cross above its 200-day moving average, trading as high as $8.43 before settling at $8.2530. The company has received varied analyst ratings, with an average target price of $48.80, and institutional investors have recently adjusted their positions. …

Adicet Bio, Inc. (NASDAQ:ACET) Receives Consensus Rating of "Moderate Buy" from Brokerages

Adicet Bio (ACET) Projected to Release Quarterly Earnings on Thursday

Adicet Bio Inc (ACET) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Adicet Bio Inc (ACET) by TradingKey, focusing on its current valuation score and P/E ratio. ACET's valuation score is 8.28, placing it 151st in the Biotechnology & Medical Research industry, with a P/E ratio of -0.60. The …

Adicet Bio Inc (ACET) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Adicet Bio Inc (ACET), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. While the stock's price momentum score is 3.90, ranking 311 out of 385 in its industry, it …

Adicet Bio Inc (ACET) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Adicet Bio Inc (ACET), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 1.29, ranking 309 out of 385 in the Biotechnology & Medical Research industry, and shows a beta …

ACET|Adicet Bio Inc|Price:8.275|Chg%:+0.075

Adicet Bio Inc (ACET) has a TradingKey Stock Score indicating weak fundamentals but high growth potential, with its valuation considered fairly valued. Institutional ownership is very high, and multiple analysts rate it as a Strong Buy with a target price of $34.833. The company …

Adicet Bio Inc (ACET) Balance Sheet

This article presents the quarterly and annual balance sheets for Adicet Bio Inc (ACET), allowing users to evaluate the company's financial health, analyze fundamentals, and calculate key ratios. It includes detailed financial data for various line items such as cash, assets, liabilities, and shareholders' …

Adicet Bio Inc (ACET) Cash Flow

This article provides a detailed historical cash flow statement for Adicet Bio Inc (ACET), including operating, investing, and financing cash flows, presented in a quarterly format. It also offers definitions and explanations for key cash flow metrics such as operating cash flow, investing cash …

Adicet Bio: A 400% Upside Bet on Gamma Delta T-Cell Data

Adicet Bio (ACET) is positioned for a potential 400% upside according to analysts, despite its micro-cap status and inherent biotech risks. The company is advancing its lead prula-cel program for autoimmune diseases with a pivotal study expected in H2 2026, and ADI-212 for prostate …

Adicet Bio Inc Revenue Breakdown – TRADEGATE:1IJ

The article provides an overview of Adicet Bio Inc (1IJ) on the Tradegate Exchange, focusing on its financial data. It lists various sections available on TradingView, such as financials, documents, news, community, and forecasts, indicating where users can find detailed information about the company's …

Adicet Bio Inc (ACET) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Adicet Bio Inc's (ACET) dividend history and stock split events. It indicates that ACET has not distributed dividends in the past five years but lists several merger-related stock splits, including a significant 16-to-1 merger scheduled for December 2025 …

Adicet Bio Market Sentiment

This article provides details on the market sentiment for Adicet Bio (ACET), including analyst consensus, short interest, options flow, and insider activity. The overall analyst consensus is a "Buy" with an average price target of $24, indicating a potential upside of 179.4%. The article …

Adicet Bio (NASDAQ:ACET) Share Price Crosses Above 200-Day Moving Average - Should You Sell?

Adicet Bio (NASDAQ:ACET) shares recently crossed above their 200-day moving average, trading at $8.12 after hitting a high of $8.31. Analyst sentiment for the clinical-stage biotechnology company has improved, with a consensus "Moderate Buy" rating and a target price of $48.80. Despite being an …

Adicet Bio Q1 2026 Earnings: EPS Surprise of 40.74% on Narrower-Than-Expected Loss, Stock Declines - Earnings Growth Analysis

Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference

Adicet Bio, Inc. announced that its President and Chief Executive Officer, Chen Schor, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The event will take place from August 11-13, 2026, in Boston, with the specific fireside chat scheduled …

Adicet Bio CEO's Aug. 11 chat includes live audio webcast

Surya Biru Murni (SBMA) Gelar RUPSLB, Ubah Susunan Direksi dan Tambah Bisnis Baru